Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 11
2019 10
2020 7
2021 11
2022 9
2023 3
2024 15
2025 10
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
Vigneswaran HT, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Eggener S, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Palsdottir T, Plym A, Wiklund F, Grönberg H, Murphy AB; SEPTA STHLM3 Study Group. Vigneswaran HT, et al. J Clin Oncol. 2024 Nov 10;42(32):3806-3816. doi: 10.1200/JCO.24.00152. Epub 2024 Jul 22. J Clin Oncol. 2024. PMID: 39038251
Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), free PSA, KLK2, GDF15, PSP94, germline risk (single-nucleotide polymorphisms), age, family history, and previous negative biopsy. ...CONCLU …
Before biopsy, sample was collected for measurement of the Stockholm3 risk score. Parameters include prostate-specific antigen (PSA), …
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H; STHLM3 study group. Nordström T, et al. Lancet Oncol. 2021 Sep;22(9):1240-1249. doi: 10.1016/S1470-2045(21)00348-X. Epub 2021 Aug 13. Lancet Oncol. 2021. PMID: 34391509 Clinical Trial.
Key secondary outcome measures included the proportion of men with clinically insignificant prostate cancer (defined as a Gleason score of 3 + 3), and the number of any prostate MRI and biopsy procedures done. We did two comparisons: Stockholm3 (using scores of 0.11 and 0. …
Key secondary outcome measures included the proportion of men with clinically insignificant prostate cancer (defined as a Gleason score of 3 …
The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A, Olsson H, Grönberg H, Eklund M, Aly M, Nordström T. Möller A, et al. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):137-142. doi: 10.1038/s41391-018-0082-5. Epub 2018 Aug 31. Prostate Cancer Prostatic Dis. 2019. PMID: 30171228
Blood samples for Stockholm3 analysis were drawn prior to systematic prostate biopsies. Clinically significant prostate cancer was defined as any finding of ISUP Grade Group (GG) 2 or higher. ...Using a Stockholm3 cut-off of 10% risk of GG 2 cancer, 38% of the biops …
Blood samples for Stockholm3 analysis were drawn prior to systematic prostate biopsies. Clinically significant prostate cancer was de …
Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
Hao S, Heintz E, Östensson E, Discacciati A, Jäderling F, Grönberg H, Eklund M, Nordström T, Clements MS. Hao S, et al. Eur Urol. 2022 Jul;82(1):12-19. doi: 10.1016/j.eururo.2021.12.021. Epub 2022 Jan 31. Eur Urol. 2022. PMID: 35094896 Free article.
BACKGROUND: Stockholm3 is a risk model that combines the prostate-specific antigen (PSA) test, other plasma protein biomarkers, single nucleotide polymorphisms, and clinical variables. ...This Stockholm3 strategy was cost-effective with a probability of 70% at a cos …
BACKGROUND: Stockholm3 is a risk model that combines the prostate-specific antigen (PSA) test, other plasma protein biomarkers, singl …
Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
Andersson J, Palsdottir T, Lantz A, Aly M, Grönberg H, Egevad L, Eklund M, Nordström T. Andersson J, et al. Eur Urol Open Sci. 2022 Aug 29;44:69-75. doi: 10.1016/j.euros.2022.08.006. eCollection 2022 Oct. Eur Urol Open Sci. 2022. PMID: 36185581 Free PMC article.
DRE is incorporated in many clinical risk calculators, but there is less evidence on how DRE performs in the setting of blood biomarkers and polygenic risk prediction models other than prostate-specific antigen (PSA) associated with prostate cancer. The Stockholm3 test com …
DRE is incorporated in many clinical risk calculators, but there is less evidence on how DRE performs in the setting of blood biomarkers and …
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
Vigneswaran HT, Palsdottir T, Micoli C, Tilki D, Lin D, Cooperberg M, Eggener S, Falagario UG, Möller A, Aly M, Akre O, Wiklund P, Egevad L, Grönberg H, Nordström T, Eklund M. Vigneswaran HT, et al. Eur Urol. 2026 Jan;89(1):82-90. doi: 10.1016/j.eururo.2025.10.001. Epub 2025 Oct 16. Eur Urol. 2026. PMID: 41107178 Free article. Clinical Trial.
Incidence across four baseline groups-(1) elevated PSA (3 ng/ml) and Stockholm3 (11), (2) elevated Stockholm3 alone (11), (3) elevated PSA alone (3 ng/ml), and (4) neither elevated PSA (<3 ng/ml) nor elevated Stockholm3 (<11)-was compared using Gray's t …
Incidence across four baseline groups-(1) elevated PSA (3 ng/ml) and Stockholm3 (11), (2) elevated Stockholm3 alone (11), (3) …
Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort.
Elyan A, Saba K, Sigle A, Wetterauer C, Engesser C, Püschel H, Attianese S, Maurer P, Deckart A, Cathomas R, Strebel RT, Gratzke C, Seifert HH, Rentsch CA, Mortezavi A. Elyan A, et al. Eur Urol Focus. 2024 Jul;10(4):620-626. doi: 10.1016/j.euf.2023.09.016. Epub 2023 Oct 7. Eur Urol Focus. 2024. PMID: 37813730 Free article.
OBJECTIVE: To assess the performance of the Stockholm3 test in discriminating csPCa in a Central European cohort undergoing prostate biopsy (PBx). ...CONCLUSIONS: Our results show favorable clinical outcomes for the blood-based Stockholm3 biomarker test in a Central …
OBJECTIVE: To assess the performance of the Stockholm3 test in discriminating csPCa in a Central European cohort undergoing prostate …
63 results